By Devika Patel
Knoxville, Tenn., May 20 - Oncothyreon Inc. has arranged an $11.06 million registered direct offering of stock, according to a prospectus supplement filed Wednesday with the Securities and Exchange Commission.
The company will sell 3,878,993 units, with each $2.85 unit consisting of one share and 0.75 of a warrant.
The warrants are exercisable at $3.92 for five years.
Boenning & Scattergood, Inc. is the agent.
Settlement is expected May 26.
Proceeds will be used for general corporate purposes.
Oncothyreon is an Edmonton, Alta., biotechnology company.
| Issuer: | Rexahn Pharmaceuticals, Inc.
|
| Issue: | Units of one share and 0.75 of a warrant
|
| Amount: | $11,055,130.05
|
| Shares: | 3,878,993
|
| Price: | $2.85
|
| Warrants: | 0.75 of a warrant per unit
|
| Warrant expiration: | Five years
|
| Warrant strike price: | $3.92
|
| Agent: | Boenning & Scattergood, Inc.
|
| Pricing date: | May 20
|
| Settlement date: | May 26
|
| Stock symbol: | Nasdaq: ONTY
|
| Stock price: | $2.82 at close May 20
|
| Market capitalization: | $55 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
